Cryoablation for T1a RCC Linked With Good Long-Term Outcomes
No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.
No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
CKD risk is increased 3.9-fold for patients who undergo radical vs partial nephrectomy.
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.